Clinical Trials
267 trialsCINC424A2X01B Rollover Protocol
Novartis
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Vanderbilt-Ingram Cancer Center
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
National Cancer Institute (NCI)
A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Ono Pharmaceutical Co., Ltd.
IMG-7289-CTP-203
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
HU-F-AIM
Novartis
MITHRIDATE
University of Birmingham
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Ohio State University Comprehensive Cancer Center
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers
Eilean Therapeutics
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
ENERGIA
University of Turin, Italy
MK-3543-017
Merck Sharp & Dohme LLC
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
University of Southern California
GIV-IN-PV
Italfarmaco
AVAJAK
University Hospital, Brest
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
University of California, Irvine
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Disc Medicine, Inc
Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Chengdu Zenitar Biomedical Technology Co., Ltd
A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV
Peking Union Medical College Hospital
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
City of Hope Medical Center
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
MPN Research Foundation
WELL-MPN
Brigham and Women's Hospital
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
Ionis Pharmaceuticals, Inc.
ACTIVAQ
Hospices Civils de Lyon
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
M.D. Anderson Cancer Center
ROPE
iOMEDICO AG
Ruxolitinib in Thrombocythemia and Polycythemia Vera
Massachusetts General Hospital
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
University of Miami
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
M.D. Anderson Cancer Center
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
CONT-LOW-PV
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
ET2PV
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
SLN
Silence Therapeutics plc
TREATMORE
Icahn School of Medicine at Mount Sinai
PHEMOP
University Hospital, Angers
POLYVISCO
Hospices Civils de Lyon
Managed Access Programs for INC424, Ruxolitinib
Novartis
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
Novartis
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
PharmaEssentia Japan K.K.
Prospero
Novartis
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Incyte Corporation